Complete Guide to CPT 83036, 82947 & 82985

Schedule Your Free Consultation

THE REVENUE PROBLEM NO ONE TALKS ABOUT

Why CPT 83036, 82947 & 82985 Are Costing Endocrinology Practices Thousands Every Month

Diabetes affects over 38 million Americans, and the lab testing that monitors it hemoglobin A1c, blood glucose, and glycated protein generates an enormous volume of claims across endocrinology and internal medicine practices every week. That volume is precisely why the billing errors around these three CPT codes are so expensive. A systematic error in how you bill CPT 83036 alone, repeated across hundreds of patients over a year, can represent $40,000 or more in denied or underpaid claims.

What makes these codes particularly dangerous from a revenue cycle standpoint is that they sit at the intersection of several billing risk factors simultaneously: frequency limitations, point-of-care versus laboratory differentiation, medical necessity documentation requirements, and overlapping payer policies that differ between Medicare, Medicare Advantage, and commercial plans.

We work with endocrinology practices and diabetes clinics that bill these codes every single day. The patterns we see in denial data are consistent: the same mistakes appear repeatedly, the same documentation gaps generate the same denial letters, and the same revenue recovery opportunities go unrecognized. This guide exists to change that for your practice in 2026.

28% of A1c claims (CPT 83036) face denial or underpayment due to frequency and documentation issues

$42K average annual revenue loss per endocrinology practice from lab billing errors on these three codes

73% of denied diabetes lab claims are recoverable with proper documentation and appeal workflow

96%+ clean claim rate achievable on CPT 83036, 82947 & 82985 with optimized billing protocols

⚠ 2026 Compliance Alert

CMS updated its National Coverage Determination guidance for diabetes monitoring in its 2026 policy cycle, including revised documentation specificity requirements for A1c testing frequency. Practices billing under pre-2025 protocols may be generating claims that are technically non-compliant with current Medicare policy, creating both denial exposure and post-payment audit risk.

CPT CODE DEEP DIVE #1

CPT 83036 — Hemoglobin A1c: The Most Billed and Most Mishandled Diabetes Lab Code

CPT 83036

Hemoglobin A1c (HbA1c) — Glycosylated Hemoglobin

Measures average blood glucose over the prior 2 to 3 months — the cornerstone of diabetes management monitoring

⚡ QUICK REFERENCE

Details

CPT Description

Hemoglobin; glycosylated (A1c)

Medicare 2026 Rate

$12.81 – $18.40 (varies by Medicare Administrative Contractor locality)

Standard Frequency

Up to 4 times per year (quarterly) for most payers; twice yearly for well-controlled patients per ADA guidelines

Key Modifiers

QW (waived test in-office), 59 (distinct procedural service), GY (non-covered), GZ (expect denial)

Primary ICD-10 Codes

E11.65, E11.9, E10.9, Z13.1, E13.9, E11.649

Payer Sensitivity

HIGH — Medicare, Medicare Advantage, and commercial plans apply frequency edits and medical necessity requirements

CPT 83036 is the most frequently billed diabetes laboratory code in endocrinology and internal medicine. It measures the percentage of glycated hemoglobin in a blood sample, reflecting average blood glucose control over the preceding two to three months. That clinical utility is precisely why payers scrutinize it carefully its frequency, medical necessity justification, and documentation are all areas where auditors look closely.

⚡ Revenue Risk: HIGH — Frequency edits and documentation gaps create significant denial volume

Most Common Billing Errors on CPT 83036

⚠ Error 1 — Missing QW Modifier on In-Office Testing

When A1c is performed in-office using a waived device, the QW modifier is mandatory. Without it, Medicare and many commercial payers will deny the claim as requiring laboratory certification. This error accounts for an estimated 18 percent of initial CPT 83036 denials in endocrinology practices.

⚠ Error 2 — Frequency Edits Without Supporting Documentation

Billing A1c more than 4 times per year without clinical documentation of medical necessity is one of the top audit targets for diabetes lab claims. Every additional A1c beyond quarterly frequency requires a physician note that specifically addresses why more frequent monitoring is clinically necessary for that patient.

⚠ Error 3 — Incorrect ICD-10 Code Selection

Using E11.9 (Type 2 diabetes without complications) when the patient has documented complications such as E11.649 results in a medical necessity mismatch that may trigger denial or audit. ICD-10 code selection must reflect the patient's actual documented condition.

💡 PRO TIP FROM MEDCLOUDMD

Build a pre-billing A1c validation workflow that checks: (1) frequency against the patient's year-to-date A1c claim history, (2) modifier appropriateness based on where the test was performed, and (3) ICD-10 alignment with the clinical note. This three-point check eliminates the vast majority of CPT 83036 denials before they occur.

CPT CODE DEEP DIVE #2

CPT 82947 — Blood Glucose (Quantitative): The Most Denied Diabetes Lab Code in 2026

CPT 82947

Glucose — Quantitative, Blood (Not Self-Monitored)

Measures blood glucose level at a specific point in time — frequently confused with patient self-monitoring, creating significant billing compliance risk

⚡ QUICK REFERENCE

Details

CPT Description

Glucose; quantitative, blood (except reagent strip)

Medicare 2026 Rate

$4.66 – $7.12 (varies by MAC locality)

Related Codes

82948 — Glucose, whole blood (reagent strip); 82950 — Glucose; post-glucose dose

Key Modifiers

QW (waived in-office), 59 (distinct service when combined with other glucose codes)

Primary ICD-10 Codes

R73.09, E11.9, E11.65, E16.0, E16.2, R73.01, Z13.88

Bundling Risk

HIGH — 82947 is subject to NCCI bundling edits with 82950 and 82951 without appropriate modifier use

CPT 82947 is the correct code for a quantitative blood glucose measurement performed in a clinical or laboratory setting not a patient's home blood glucose reading. Confusing 82947 with patient self-monitoring codes, or billing 82947 when what was actually performed corresponds to a different glucose code, is one of the top compliance risks in diabetes billing.

⚡ Revenue Risk: VERY HIGH — Bundling edits, code confusion, and medical necessity gaps create layered denial exposure

Critical Billing Issues for CPT 82947

🔔 The 82947 vs 82948 Confusion

CPT 82948 describes glucose testing using a whole blood reagent strip — essentially, an office glucometer test. CPT 82947 is the quantitative laboratory glucose test. Mismatching the code to the actual testing methodology is a compliance risk that appears frequently in endocrinology audits.

⚠ NCCI Edit Violations

Billing 82947 and 82950 together without modifier 59 and supporting documentation is one of the most common NCCI bundling violations in diabetes billing. CMS's claim editing system flags these combinations automatically, and payments made without proper modifier support are subject to recoupment on audit.

✅ Revenue Recovery Opportunity

Many endocrinology practices that perform quantitative glucose testing as part of their diabetes monitoring protocol are either not billing 82947 at all or billing the wrong code variant. A coding audit specifically looking at glucose testing claims often uncovers $8,000 to $15,000 annually in unbilled or under-billed laboratory revenue.

CPT CODE DEEP DIVE #3

CPT 82985 — Glycated Protein (Fructosamine): The Underused Code With Significant Revenue Potential

CPT 82985

Glycated Protein (Fructosamine / Glycoalbumin)

Measures short-term glycemic control over the prior 2 to 3 weeks — a critical tool when A1c is unreliable, yet frequently underbilled or unbilled entirely

⚡ QUICK REFERENCE

Details

CPT Description

Glycated protein

Medicare 2026 Rate

$11.42 – $16.80 (varies by MAC locality)

Clinical Indication

When A1c is unreliable: hemolytic anemia, hemoglobinopathies (sickle cell), pregnancy, recent blood transfusion, ESRD

Key Modifiers

59 (when billed alongside A1c or other glycemic tests), 91 (repeat test)

Primary ICD-10 Codes

E11.9, D57.1, D58.9, Z34.00, N18.6, E11.65, D64.9

Documentation Requirement

CRITICAL — must document why A1c is unreliable; without this, most payers deny as duplicate or non-covered

Of the three codes covered in this guide, CPT 82985 is the one most often left on the table. Many endocrinology practices that regularly care for patients with hemolytic anemia, sickle cell disease, pregnancy-related diabetes, or end-stage renal disease are performing glycated protein testing and either not billing for it at all, or billing it under a miscellaneous code that reimburses at a fraction of the correct rate.

⚡ Revenue Risk: MEDIUM — Underbilling and missing documentation are the primary issues

💵 Revenue Opportunity: HIGH — Many practices are leaving $10K–$20K/year unbilled on this code

Unlocking the Revenue Potential of CPT 82985

✅ Identifying Unbilled 82985 Patients

Pull your patient roster and identify patients with sickle cell disease (D57.x), hemolytic anemia (D58.x), active pregnancy with diabetes (O24.x), or ESRD (N18.6) who have had glycated protein testing performed. Then compare that list against your billing history for CPT 82985. The gap between tests performed and tests billed is your unbilled revenue. In our experience, this gap averages $12,000 to $22,000 annually.

💡 PRO TIP FROM MEDCLOUDMD

Create a standard documentation phrase that physicians can insert into relevant patient notes: "Hemoglobin A1c measurement is unreliable for this patient due to [condition]. Glycated protein (fructosamine) testing is being performed to assess glycemic control over the past 2 to 3 weeks as an alternative measure." This language directly addresses payer medical necessity requirements and significantly reduces denial rates on this code.

SIDE-BY-SIDE ANALYSIS

CPT 83036, 82947 & 82985 — Complete Comparison Table 2026

ICD-10 CODING GUIDANCE

ICD-10 Code Mapping for Diabetes Lab Testing 2026 Reference

Accurate ICD-10 code selection is the most common differentiator between a clean claim and a denial on CPT 83036, 82947, and 82985.

💡 PRO TIP FROM MEDCLOUDMD

Medicare and many commercial payers increased their focus on ICD-10 specificity for diabetes claims in 2026. Using E11.9 when the patient has documented complications such as nephropathy (E11.65) or retinopathy (E11.311) can weaken medical necessity documentation and create audit vulnerability. Code to the highest level of specificity that the clinical documentation supports.

DENIAL PREVENTION INTELLIGENCE

Common Denial Reasons for CPT 83036, 82947 & 82985 — and How to Prevent Every One

⚠ 2026 Audit Watch — Diabetes Lab Claims

CMS's Recovery Audit Contractor program identified diabetes laboratory testing as a 2026 audit focus area. Practices billing CPT 83036 more than 4 times per year for more than 20 percent of their diabetic patient panel without corresponding frequency justification should conduct an internal audit before a RAC audit does it for them.

BILLING OPERATIONS

Step-by-Step Diabetes Lab Billing Workflow — 2026 Best Practice

A clean claim on CPT 83036, 82947, or 82985 is the result of a disciplined sequence of pre-billing steps, not just accurate code selection at the end.

📋 Order Review

✅ Eligibility & Benefits

📊 Frequency History

📝 Documentation Validation

🔢 CPT & ICD-10

🔍 Modifier Review

🔄 Claim Scrubbing

📤 Submit & Manage

Workflow Step	What to Check	Common Failure Point	Time Required
Order Review	Test ordered matches test performed; physician documented clinical indication in note on DOS	Test performed does not match order; indication not in note on DOS	2–3 minutes per claim
Eligibility & Benefits	Active coverage; lab benefits included; in-network status; Medicare Advantage vs. traditional Medicare	MA plan has different lab coverage than traditional Medicare	1–2 minutes (automated)
Frequency History	Patient year-to-date A1c claim count; any same-day duplicate risk	4th A1c submitted without checking prior three are processed	1–2 minutes
Documentation Validation	82985 — A1c unreliability statement present; 83036 above quarterly — frequency justification in note	Missing documentation discovered after denial rather than before submission	3–5 minutes
CPT & ICD-10	Code matches test performed; ICD-10 at highest specificity	Generic E11.9 used when more specific code with complications is documented	2–3 minutes
Modifier Review	QW for in-office waived tests; 59 for multiple glucose codes same day	QW forgotten on in-office A1c; 59 missing on bundled glucose codes	1–2 minutes
Claim Scrubbing	NCCI edits cleared; payer-specific 2026 edits cleared; required fields populated	Scrubber not updated with 2026 payer policy changes	Automated

REAL-WORLD BILLING PRACTICE

Real-World Billing Scenarios — How These Codes Work in Practice

Scenario 1 — Correct Billing — Quarterly A1c with In-Office Testing

A 58-year-old Type 2 diabetic patient presents for her quarterly diabetes management visit. The physician orders an A1c using the in-office CLIA-waived device. The A1c is performed before the visit and results are reviewed during the encounter.

Correct Billing: CPT 99214 (office visit) + CPT 83036-QW (in-office A1c with waived modifier) + ICD-10 E11.65 (Type 2 diabetes with hyperglycemia). Both charges are separately billable. The QW modifier correctly identifies this as a CLIA-waived test.

✅ Result: Clean Claim — Full Reimbursement

This claim submits cleanly and reimburses within 14 to 21 days. No denial risk when coded correctly with the QW modifier and appropriate ICD-10 specificity.

Scenario 2 — Revenue Recovery Opportunity — CPT 82985 Not Being Billed

A 44-year-old patient with known sickle cell disease (D57.1) and Type 2 diabetes is being monitored for glycemic control. Because of his hemoglobinopathy, A1c values are unreliable. The endocrinologist orders glycated protein testing monthly. The practice has been billing the office visit but not the lab test.

Correct Billing: CPT 82985 (glycated protein) is separately billable with ICD-10 codes E11.9 and D57.1. The physician note must state: "HbA1c is unreliable due to hemoglobinopathy (sickle cell disease). Fructosamine testing is ordered as an alternative measure of glycemic control."

💰 Revenue Recovery: $3,900–$5,100 per year from 25 similar patients

At approximately $13 to $17 per claim (Medicare rate), billing 82985 monthly represents $156 to $204 annually per patient. For a practice with 25 similar patients, that is $3,900 to $5,100 per year in previously unbilled revenue from a single code.

Scenario 3 — Common Billing Error — Fifth A1c Without Frequency Justification

A 67-year-old Medicare patient with poorly controlled Type 2 diabetes has already had four A1c tests this calendar year. In November, the physician orders a fifth A1c because the patient started a new GLP-1 receptor agonist in October. The billing team submits without reviewing the year-to-date A1c count or ensuring the physician note documents the clinical rationale.

What Happens: Medicare applies its frequency edit and denies the claim as exceeding the standard frequency limitation. The claim generates a CO-119 denial code (benefit maximum reached).

🔴 Denial Received — Preventable with Pre-Submission Documentation Review

The physician's note must explicitly document: "Fifth A1c is medically necessary for this patient due to initiation of new GLP-1 therapy in October 2026. Monitoring response to new agent requires assessment of glycemic trend sooner than quarterly schedule." With this documentation, the claim can be appealed successfully or submitted with justification attached upfront to prevent the denial.

PAYER POLICY REFERENCE

Frequency, Modifier & Payer Policy Reference Table 2026

Policy Area	CPT 83036 — A1c	CPT 82947 — Glucose	CPT 82985 — Glycated Protein
Medicare Frequency Limit	4x/year standard; additional requires justification	No specific limit — medical necessity	No specific limit — medical necessity
Medicare Advantage	Varies by plan; many mirror traditional Medicare	Varies by plan; some apply prior auth above 4/year	Check local plan policy — widely variable
Commercial Payers	Most follow quarterly standard	Generally no limit with medical necessity	Coverage varies; pre-auth may be required
Medicaid (state-dependent)	Varies by state; most follow 4x/year	Generally covered with medical necessity	Highly variable; check state-specific policy
QW Modifier Required	Yes — in-office CLIA-waived testing only	Yes — in-office CLIA-waived testing only	Rarely — typically reference lab
ABN Recommended	Yes — when 5th+ A1c in a year is anticipated	Yes — when same-day duplicate risk exists	Yes — when MAC local coverage is uncertain
RAC Audit Risk 2026	HIGH	MODERATE	LOW-MODERATE

FINAL ACTION PLAN

Billing Optimization Checklist — CPT 83036, 82947 & 82985

Use this checklist to audit your current billing process. Every unchecked item represents a potential source of denied or underpaid claims:

•       ☐ Pre-submission frequency check on CPT 83036 — year-to-date A1c count verified against patient billing history before claim is submitted

•       ☐ QW modifier applied to all in-office CLIA-waived A1c and glucose tests; reference lab tests confirmed as not carrying QW

•       ☐ ICD-10 codes selected at highest documented specificity — E11.65, E10.65, E11.649 used when complications are documented, not defaulting to E11.9

•       ☐ Documentation template in place for CPT 82985 — physician note includes explicit A1c unreliability statement with clinical rationale

•       ☐ NCCI bundling edits reviewed for same-day glucose code combinations; modifier 59 applied with supporting documentation when needed

•       ☐ MAC local coverage policy verified for CPT 82985 in your geographic area; ABN process in place for uncertain coverage situations

•       ☐ Patient roster reviewed for sickle cell, hemolytic anemia, ESRD, and pregnancy patients to identify unbilled CPT 82985 revenue

•       ☐ Claim scrubber updated with 2026 payer policy changes for diabetes lab codes including updated frequency and modifier requirements

•       ☐ Denial management workflow established specifically for these codes — denials worked within 10 business days with appeal deadline tracking

•       ☐ Quarterly internal audit in place to review denial reason codes for CPT 83036, 82947, and 82985 and identify systematic billing issues

WHY MEDCLOUDMD

Why Endocrinology Practices Trust MedCloudMD with Their Most Complex Billing

Endocrinology revenue cycle management is not a specialty that rewards generalists. The documentation complexity of diabetes lab billing, frequency edit management, modifier decision-making, and payer-specific policy navigation that these three CPT codes require all demand a billing team with focused expertise in endocrinology and laboratory medicine billing.

🎯 Endocrinology Billing Specialists Dedicated billing professionals who know CPT 83036, 82947, and 82985 inside out — including every payer's frequency policy and modifier requirement.	🔍 Pre-Submission Claim Review Every diabetes lab claim goes through a specialty-specific pre-submission audit that catches frequency, modifier, and ICD-10 issues before they reach the payer.
🔄 Denial Recovery Workflows Structured appeal processes for each common denial type on these three codes, with documented appeal success rates that consistently exceed 75 percent.	📊 Monthly Performance Reporting Denial rate by CPT code, clean claim rate trends, AR aging, and revenue per encounter benchmarked against endocrinology specialty averages.
🔬 Lab Revenue Audits We identify unbilled CPT 82985 patients, under-billed A1c claims, and incorrect code usage that practices have been losing revenue on for years.	📋 Documentation Improvement We work directly with physicians to implement documentation templates that satisfy payer requirements without adding clinical burden.

EXPERT Q&A

Frequently Asked Questions — CPT 83036, 82947 & 82985 Billing

Can CPT 83036 and 82947 be billed on the same date of service?

Yes, they can be billed on the same date of service when both tests are medically necessary and separately performed. The clinical note must document the distinct clinical rationale for each test. For example, the A1c (83036) provides long-term glycemic trend data while the glucose (82947) addresses an acute concern such as hypoglycemia or immediate glucose management. Some payers will review same-day billing of both codes for medical necessity, so documentation must be specific and sufficient to support both tests independently.

When is modifier QW required on CPT 83036?

Modifier QW is required when CPT 83036 is performed using a CLIA-waived testing device in the office setting for example, a point-of-care A1c analyzer. The QW modifier identifies this as a waived test. When the A1c specimen is collected in the office but sent to an external reference laboratory for processing, the QW modifier is not applicable the reference lab should bill the A1c under their own NPI without QW. Applying QW to reference lab claims is a compliance error.

How many times per year can Medicare pay for CPT 83036?

Medicare covers CPT 83036 up to four times per year (quarterly) for diabetic patients as standard frequency. For patients who need more frequent monitoring unstable glycemic control, new diabetes diagnoses, or recent medication changes additional A1c tests beyond four per year require clinical documentation in the physician note explaining why the additional frequency is medically necessary. These additional tests are subject to medical necessity review and should have clear, specific documentation before the fifth or subsequent claim is submitted.

What documentation is required to bill CPT 82985 successfully?

CPT 82985 requires two key documentation elements. First, the clinical note must explicitly state that hemoglobin A1c is unreliable for this patient and identify the specific clinical reason hemoglobinopathy, hemolytic anemia, end-stage renal disease, active pregnancy, or recent blood transfusion. Second, the ICD-10 code should include both the diabetes diagnosis and the condition making A1c unreliable. Without the A1c unreliability statement, most payers treat 82985 as a duplicate of 83036 and deny it.

What does denial code CO-119 mean on a CPT 83036 claim?

CO-119 is the CARC (Claim Adjustment Reason Code) for "Benefit maximum for this time period or occurrence has been reached." On CPT 83036 claims, it indicates the patient has reached the payer's frequency limit for A1c testing most commonly four tests per year for Medicare. Options are: (1) appeal with clinical documentation justifying additional frequency, (2) bill the patient with an ABN if one was collected before the service, or (3) write off the charge if no ABN was collected and the denial is non-appealable.

Is CPT 82985 covered by all Medicare plans?

No — CPT 82985 does not have a National Coverage Determination from CMS, which means coverage is determined by the Local Coverage Determination of the Medicare Administrative Contractor serving your geographic area. Coverage varies significantly between MAC jurisdictions. Before billing CPT 82985 to Medicare patients, verify your MAC's local coverage policy. If coverage is uncertain, an Advance Beneficiary Notice (ABN) should be collected from the patient before the service to protect your ability to collect from the patient if Medicare denies the claim.

What is the difference between CPT 82947 and CPT 82948?

CPT 82947 describes a quantitative glucose test performed using laboratory methodology. CPT 82948 describes a glucose test performed using a whole blood reagent strip essentially, the type of glucometer test performed in a physician's office. When an office glucometer is used and the test is performed as a CLIA-waived test, 82948 with modifier QW is typically the correct code. Using 82947 when 82948 applies or billing both when only one was performed creates compliance exposure commonly identified in billing audits of endocrinology practices.

Can endocrinology practices bill for lab tests performed by a reference laboratory?

This depends on your billing arrangement with the reference laboratory. In most standard arrangements, the reference laboratory bills for the laboratory test directly under its own NPI and CLIA number, and the endocrinology practice bills only for the interpretation of results (when applicable) or the office visit. Attempting to bill for laboratory services performed by an external reference lab under your practice's NPI without a compliant purchased diagnostic test arrangement is a billing compliance issue.

YOUR NEXT STEP

Stop Losing Revenue on Diabetes Lab Billing — Start Optimizing It

Many endocrinology practices lose $30,000 to $60,000 annually in denied, underpaid, or simply unbilled claims on CPT 83036, 82947, and 82985. MedCloudMD's endocrinology billing specialists identify exactly where your practice is losing revenue and implement the coding, documentation, and denial management workflows to recover it.

🚀 Request Your Free Endocrinology Billing Consultation — 2026

www.medcloudmd.com/specialties/endocrinology-billing-services

🔍 Free Billing Audit   📊 Denial Analysis   💰 Revenue Recovery Plan   ⚡ Fast Onboarding

HIPAA Compliant  |  No Obligation  |  CPT 83036 · 82947 · 82985 Specialists  |  All Payers